Legislator Brief · one page · drafted to be printed and carried into a meeting
Laboratory quality as payment integrity
A test that is known not to work should stop generating clean claims before it becomes a fraud case.
Object type
Legislator Brief
Label
MODEL CMS POLICY
Status
OPEN FOR CRITIQUE
Jurisdiction
Federal
Domain
Drug & device regulation
Baseline verified
2026-08-30
Issue
Payment for a laboratory test does not depend on whether the test performs as claimed for the clinical use billed, so a known analytic failure can continue to generate clean claims.
Why now
High-volume testing under laboratory-developed-test pathways has outrun the oversight designed for it, and the enforcement record shows failures persisting through billing cycles.
Current law
CLIA governs laboratory operations and quality control; FDA asserts device authority over certain tests; Medicare pays on coding and coverage rules that do not incorporate performance characteristics for the billed use.
Policy gap
Quality oversight and payment integrity are separate systems, so a quality failure has no payment consequence until it becomes a fraud case.
KPSGILL recommendation
Make performance characteristics for the billed clinical use a condition of payment, require an annual quality-control attestation above a volume threshold, and treat claims for results from a known failed process as improper payments with a thirty-day clinician notice duty.
Who can act
Cost
Analysis, not projection. Attestation cost falls on laboratories above the volume threshold. Programme savings come from recoveries and deterrence, magnitude unknown. Small-laboratory exposure is the principal cost risk and is why the threshold exists.
Trade-offs
| Dimension | Direction | Basis |
|---|---|---|
| Patient safety | ↑ increase | Notice is the mechanism, not the payment penalty. |
| Government cost | ↓ decrease | Recovery and deterrence, offset by administration. |
| Administrative complexity | ↑ increase | One attestation cycle plus a notice duty. |
| Innovation | ± mixed | Raises the cost of bringing a test to market on thin validation. Intended. |
| Access | ~ uncertain | If small laboratories exit, rural access falls; the threshold and a phase-in must be sized against that. |
| Competition | ± mixed | Favours laboratories that already validate; consolidates at the margin. |
Who is affected
| Group | Expected impact | Why |
|---|---|---|
| Patients | strongly favorable | Notice when a result they were treated on came from a failed process. |
| Physicians | favorable | Learn of a failure while the patient is still treatable. |
| Government | favorable | Payment lever available before a fraud theory is required. |
| Hospitals | mixed | Outreach laboratories take on attestation duty. |
| Device manufacturers | unfavorable | Performance claims become payment-relevant. |
| Insurers | favorable | Same lever available in private coverage terms. |
Policy options
Option A — status quo
Quality and payment stay separate; failures are addressed as fraud, years later.
Option B — limited reform
Strengthen CLIA proficiency requirements without touching payment. Leaves the incentive untouched.
Option C — structural reform
Performance characteristics as a condition of payment, with attestation, known-failure rule and clinician notice.
Option D — KPSGILL preferred · preferred
C with a volume threshold, a phase-in, and the clinician-notice duty effective first — the notice is the patient-safety instrument and should not wait for the payment rule.
How we would know it worked
- Laboratories attesting, by volume band
- Known-failure notices issued, and time from detection to notice
- Improper-payment recoveries attributable to the rule
- Rural laboratory participation before and after phase-in
The five-physician practice
Ordering clinicians gain a notice right and take on no attestation duty; the volume threshold keeps the burden off small independent laboratories.
Next decision point
The next Medicare clinical-laboratory payment rulemaking; any CLIA proficiency-testing revision.
Model language and sources
Model statutory or regulatory language, the documentary baseline it rests on, the strongest arguments against the proposal and the KPSGILL responses to them are on the full page: Laboratory quality as payment integrity. Related briefs are indexed at Legislator Briefs.